Optimal timing of post-operative albendazole prophylaxis in <i>E. granulosus</i>

Morris, D. L.; Taylor, D. H.

doi:10.1080/00034983.1988.11812210

Cited by 34 publications

(26 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results matched those found in vivo (Morris et al 1986;Morris and Taylor, 1988;PeÂ rez-Serrano et al 1997). Because of the good results obtained, this drug is more commonly used in clinical practice today than previously (Gil-Grande et al 1993).…”

Section: Introductionsupporting

confidence: 88%

Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?

Moreno

Casado²,

Urrea-París³

et al. 2002

Parasitol Res

View full text Add to dashboard Cite

The efficacy of ivermectin (IVM) alone, albendazole (ABZ) alone and a combination of both (IVM + ABZ) against Echinococcus granulosus protoscolices was studied by means of in vitro incubation. The maximum protoscolicidal effect was detected when we used IVM+ABZ in combination. In this case, protoscolex viability dropped to 35% in comparison with 50% for IVM alone and 82.5% with ABZ alone 18 days post-incubation. Only the protoscolices incubated with IVM + ABZ did not develop into cysts following their inoculation into mice. The changes in ultrastructure induced in the protoscolices after the different drug incubations are also described. The incubation of cysts with IVM and IVM + ABZ shows that IVM + ABZ in combination is more effective than IVM alone as only when we incubated the cysts with IVM + ABZ did they completely lose their infectivity to mice. This occurred after only 10 days post-incubation. Cellular alterations were also more marked with IVM+ABZ incubations with: (1) the presence of residual bodies, (2) numerous lipids droplets and (3) vacuoles in the cytoplasm of cytons. However, the truncated microtriches and the nuclei remained unaltered after 10 days.

show abstract

Section: Introductionsupporting

confidence: 88%

Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?

Moreno

Casado²,

Urrea-París³

et al. 2002

Parasitol Res

View full text Add to dashboard Cite

show abstract

“…In addition, as previously indicated medical treatment with albendazole before surgery allows relapses to be reduced. 36,37 Other anti-parasitic drugs have been tested in combination with benzimidazoles with a synergic action. Although there are no comparative randomized studies exploring treatment with albendazole in monotherapy versus combined therapy with albendazole plus praziquantel in patients without surgery, it appears that the combined therapy could improve the results obtained with albendazole alone.…”

Section: Discussionmentioning

confidence: 99%

Safety of the Combined Use of Praziquantel and Albendazole in the Treatment of Human Hydatid Disease

Alvela-Suárez

Velasco‐Tirado

Belhassen-García³

et al. 2014

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. There is still no well-established consensus about the clinical management of hydatidosis. Currently, surgery continues to be the first therapeutic option, although treatment with anti-parasitic drugs is indicated as an adjuvant to surgery to decrease the number of relapses and hydatid cyst size. When surgery is not possible, medical treatment is indicated. Traditionally, albendazole was used in monotherapy as the standard treatment. However, combined therapy with albendazole plus praziquantel appears to improve anti-parasitic effectiveness. To date, no safety studies focusing on such combined therapy have been published for the treatment of hydatidosis. In this work, we analyze the adverse effects seen in 57 patients diagnosed with hydatidosis who were treated with praziquantel plus albendazole combined therapy between 2006 and 2010.

show abstract

“…For the PAIR technique (see below), experts recommend chemotherapy with albendazole 24 to 4 h before intervention and 15 to 30 days afterwards (222). The number of E. granulosus cysts developing from intraperitoneally inoculated protoscoleces in rodents could be reduced by 80 to 90% if albendazole treatment (10 mg/kg of body weight/day) for 1 week was initiated immediately after inoculation, but treatment starting 15 days after inoculation was ineffective (143). Data on praziquantel treatment are contradictory.…”

Section: Vol 17 2004 Biology and Epidemiology Of Echinococcosis 109mentioning

confidence: 99%

Biological, Epidemiological, and Clinical Aspects of Echinococcosis, a Zoonosis of Increasing Concern

2004

View full text Add to dashboard Cite

Echinococcosis in humans is a zoonotic infection caused by larval stages (metacestodes) of cestode species of the genus Echinococcus. Cystic echinococcosis (CE) is caused by Echinococcus granulosus, alveolar echinococcosis (AE) is caused by E. multilocularis, and polycystic forms are caused by either E. vogeli or E. oligarthrus. In untreated cases, AE has a high mortality rate. Although control is essentially feasible, CE remains a considerable health problem in many regions of the northern and southern hemispheres. AE is restricted to the northern hemisphere regions of North America and Eurasia. Recent studies have shown that E. multilocularis, the causative agent of AE, is more widely distributed than previously thought. There are also some hints of an increasing significance of polycystic forms of the disease, which are restricted to Central and South America. Various aspects of human echinococcosis are discussed in this review, including data on the infectivity of genetic variants of E. granulosus to humans, the increasing invasion of cities in Europe and Japan by red foxes, the main definitive hosts of E. multilocularis, and the first demonstration of urban cycles of the parasite. Examples of emergence or reemergence of CE are presented, and the question of potential spreading of E. multilocularis is critically assessed. Furthermore, information is presented on new and improved tools for diagnosing the infection in final hosts (dogs, foxes, and cats) by coproantigen or DNA detection and the application of molecular techniques to epidemiological studies. In the clinical field, the available methods for diagnosing human CE and AE are described and the treatment options are summarized. The development of new chemotherapeutic options for all forms of human echinococcosis remains an urgent requirement. A new option for the control of E. granulosus in the intermediate host population (mainly sheep and cattle) is vaccination. Attempts are made to reduce the prevalence of E. multilocualaris in fox populations by regular baiting with an anthelmintic (praziquantel). Recent data have shown that this control option may be used in restricted areas, for example in cities, with the aim of reducing the infection risk for humans

show abstract

Optimal timing of post-operative albendazole prophylaxis in E. granulosus

Cited by 34 publications

References 5 publications

Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?

Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?

Safety of the Combined Use of Praziquantel and Albendazole in the Treatment of Human Hydatid Disease

Biological, Epidemiological, and Clinical Aspects of Echinococcosis, a Zoonosis of Increasing Concern

Contact Info

Product

Resources

About